Expression of programmed death receptor ligand 1 in melanoma may indicate tumor progression and poor patient survival  Junna Oba, MD, PhD, Takeshi Nakahara, MD, PhD, Takeru Abe, MA, PhD, Akihito Hagihara, DMSc, MPH, Yoichi Moroi, MD, PhD, Masutaka Furue, MD, PhD  Journal of the American Academy of Dermatology  Volume 70, Issue 5, Pages 954-956 (May 2014) DOI: 10.1016/j.jaad.2014.01.880 Copyright © 2014 American Academy of Dermatology, Inc. Terms and Conditions

Fig 1 A, Table and graphic results of immunohistochemical staining for PD-L1 in each group. A semiquantitative assessment was performed as previously described,3,4 according to the following scale: −, <5%; +, 5%-25%; 2+, 26%-50%; 3+, >50% of the tumor cells were positive. (*Nevus vs thick (pT3, pT4) melanoma, P < .0001; †thin (Tis-pT2) vs thick (pT3, pT4) melanoma, P < .0001; ‡thin vs metastatic melanoma, P = .002.) B, Survival curves showing the relationship between PD-L1 expression and patient survival. Kaplan-Meier curves of overall survival for 77 patients with melanoma with regard to tumoral PD-L1 expression (negative vs positive). The P value was calculated with the log-rank test. The overall survival of patients with PD-L1 (+) tumors (solid line) was significantly worse than that of patients with PD-L1 (−) tumors (dotted line) (P = .0023). Journal of the American Academy of Dermatology 2014 70, 954-956DOI: (10.1016/j.jaad.2014.01.880) Copyright © 2014 American Academy of Dermatology, Inc. Terms and Conditions